Rising Pharma Exports Push India To 11th Ranking FY 2025 Globally

Table of Content


New Delhi, Mar 12 (KNN) India’s pharmaceutical sector has achieved a significant global milestone, ranking 11th worldwide in export value during 2023 and capturing 3 percent of the global pharmaceutical export market, according to a research report published by Bain and Company.

The fourth quarter of fiscal year 2025 witnessed a notable surge in pharmaceutical exports, with Contract Development and Manufacturing Organisations (CDMOs) emerging as primary growth drivers for the sector. 

Despite this positive development, the generic drug segment continues to face significant pressure, with the sluggishness observed in the second and third quarters extending into the fourth quarter and adversely affecting overall performance in this category.

Union Minister of State for Chemicals and Fertilisers, Anupriya Patel, addressed regulatory measures during a written reply in the Rajya Sabha, outlining various initiatives implemented by the Central Drugs Standard Control Organisation (CDSCO) and the Ministry of Health and Family Welfare to maintain high standards of quality, safety, and efficacy in pharmaceutical products.

The Minister highlighted that the Central Government regularly conducts residential and regional training programs and workshops for officials from CDSCO and State Drug Regulatory Authorities, focusing on Good Manufacturing Practices. 

Additionally, the government coordinates activities between State Drug Control Organisations and provides expert guidance through Drugs Consultative Committee meetings.

Patel also referenced several amendments to existing legislation, including modifications to The Drugs Rules, 1945, and the Drugs and Cosmetics Act, 1940, which aim to create a more favorable business environment for industry participants.

Industry experts have expressed concern regarding recently enhanced tariffs on pharmaceutical imports, warning that these measures could significantly impact Indian pharmaceutical companies by increasing production costs and potentially reducing the competitiveness of Indian exports compared to products from other countries.

The situation has gained particular relevance following US President Donald Trump’s recent announcement that reciprocal tariffs on countries imposing high duties on US products will take effect on April 2. 

President Trump specifically identified India as a nation with high tariff rates on imported goods.

(KNN Bureau)



Source link

AIMPWA

mmkrishnandasu@gmail.com http://msmenews.sbs

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent News

Trending News

Editor's Picks

Sun Pharma is betting big on speciality. Will it pay off?

Sun Pharmaceutical Industries Ltd’s latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business–an area of focus. Checkpoint is an immunotherapy and targeted oncology company. The move will help Sun Pharma expand its portfolio of products for skin cancer within the speciality business. The key product owned by Checkpoint is Unloxcyt,...

HDFC Bank has launched Project HAKK (Hawai Anubhavi Kalyan Kendra) to provide support and services to Indian Air Force (IAF) pensioners, veterans and their families.

HDFC Bank has launched Project HAKK (Hawai Anubhavi Kalyan Kendra) to provide support and services to Indian Air Force (IAF) pensioners, veterans and their families. In this regard, the Bank has signed a Memorandum of Understanding (MoU) with the IAF acting through the office of the Assistant Chief of Air Staff – Accounts & Air...

Broker’s call: ITC Hotels – The Hindu BusinessLine

Target: ₹230 CMP: ₹166.80 Backed by a $58 billion conglomerate, ITC Hotels is India’s 2/4 hospitality chain based on operational hotels/keys. ITC Hotels operates through 6 brands, with differentiated positioning; having a portfolio of ~13k operational keys and ~4.3k keys in pipeline; the upcoming pipeline predominantly includes WelcomHotel (42%) and Fortune (33%)  With 80 per...

Nvidia stock may be a bargain. It’s cheaper than Starbucks.

Nvidia—the stock market’s AI darling—is not only cheap in historical terms, but it is notably less expensive than some other stocks you might not expect. Nvidia stock is one of, if not the most, frequently discussed artificial-intelligence trades on Wall Street. Its AI chips are the most popular, which lifted sales 114% to $130.5 billion...

ALL INDIA MSMES PROMOTION AND WELFARE ASSOCIATION

Quick Links

Popular Categories

Must Read

AIMPWA © 2025- All Right Reserved. Designed and Developed by  growGX.com